Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2000

View Archived Issues

Longer term Panretin therapy improves response rate

Allergan and Xoma expand rBPI ophthalmic program

Abciximab complements PTCA in patients with AMI

Aurora Biosciences to collaborate with Cystic Fibrosis Foundation

Early results from first hemophilia B AAV-mediated gene therapy study

The corticotropin-releasing factor receptor antagonist antalarmin reduces stress in monkeys

Parathyroid hormone-related protein analogue aids in bone healing in rabbits

AxyS continues phase II study of tryptase inhibitor as ulcerative colitis treatment

Abbott submits NDA for novel HIV therapy

Amylin initiates phase I clinical studies for atherosclerosis/restenosis drug

MorphoSys enters HuCAL agreements with Genentech and ProChon Biotech

Combined AT1 blockade/ACE inhibition reduces blood pressure, protects kidney in CALM study

Novel spiroketal-containing macrolide with cytotoxic properties isolated from Micromonospora

Potent, broad-spectrum and orally active MMP inhibitor under evaluation at Ono

First clinical results reported for BMS-214662 at recent cancer meeting

CI-1042 (Onyx-015) extensively covered at ASCO meeting; preclinical and clinical results reported

American Biogenetic Sciences to accelerate ABS-205 development for AD

U.S. Federal Trade Commission clears alliance between Kos and DuPont

Abbott discloses potential new treatments for urinary incontinence and sexual dysfunction

Worldwide approval sought for novel allergy and asthma therapy Xolair

DHFR inhibitors and their use in rheumatic conditions

Synthesis and pharmacological activity of new hypolipidemic agents from Nippon Soda

New Snow Brand compounds inhibit neuronal apoptosis

NeuroSearch presents potent new chloride channel blockers for sickle cell disease

Compositions for radioimmunotherapy and diagnosis of tumors containing new chelating agents

Pyrazolopyridine adenosine antagonists, their activity and use described by Fujisawa

New N-type calcium channel blockers synthesized at Ajinomoto

Akzo Nobel's new thrombin inhibitors presented in patent literature

Major milestones achieved in development of Palatin's LeuTech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...